NDAORALSOLUTIONPriority Review
Approved
May 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
5/8 — Partial
Priority Review
NYMALIZE (nimodipine) by R-Pharm US is calcium channel antagonists [moa]. First approved in 2013.
Drug data last refreshed 50m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYMALIZE is an oral solution formulation of nimodipine, a dihydropyridine calcium channel blocker used to reduce the incidence and severity of ischemic deficits following subarachnoid hemorrhage. It works by antagonizing calcium influx into vascular smooth muscle cells, promoting vasodilation and improving cerebral blood flow. The product represents a reformulation of an existing molecule into a more convenient dosage form.
$0.066MPart D
Peak11.8 years to LOEProduct is at peak lifecycle with minimal Part D penetration (13 claims in 2023), suggesting limited commercial expansion opportunity and a stable, smaller team structure.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia
Started Feb 2021
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1
36 enrolled
AIDS Dementia ComplexHIV Infections
Career Relevance
Working on NYMALIZE offers stability and specialized expertise in a niche therapeutic area (cerebrovascular disease) but limited career growth due to minimal commercial scale (13 Part D claims annually) and zero linked job openings. This is a specialty maintenance role suited for professionals seeking stable, focused work rather than high-growth opportunity.
Worked on NYMALIZE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.